Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy

What happened: Travere Therapeutics (Nasdaq: TVTX) presented new biomarker data from the Phase 3 PROTECT Study at ASN Kidney Week 2026, suggesting FILSPARI (sparsentan) may modify the underlying disease pathophysiology in IgA nephropathy. Key numbers: 404 adult patients enrolled in PROTECT; 295 participated in the biomarker analysis. Why it matters: Travere's chief medical officer said the totality of evidence supports FILSPARI as a non-immunosuppressive, kidney-targeted, foundational first-line treatment for IgA nephropathy. Market: -4.5% today ($50.08), +26.7% YTD, 1.3x vol — as of 22:46 UTC

Travere Therapeutics (Nasdaq: TVTX) presented new biomarker data from the Phase 3 PROTECT Study at ASN Kidney Week 2026, suggesting FILSPARI (sparsentan) may modify the underlying disease pathophysiology in IgA nephropathy.

Travere's chief medical officer said the totality of evidence supports FILSPARI as a non-immunosuppressive, kidney-targeted, foundational first-line treatment for IgA nephropathy. Market: -4.5% today ($50.08), +26.7% YTD, 1.3x vol — as of 22:46 UTC